This post was originally published on this site
Investing.com — Gilead Sciences (NASDAQ:GILD) on Wednesday said it was “aware of positive data” emerging from the National Institute of Allergy and Infectious Diseases’ (NIAID) study of its antiviral drug remdesivir for the treatment of COVID-19.
“We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing,” the company added.
Remdesivir, which has not yet been approved for use anywhere, has been touted as one of the most promising potential cures for the Covid-19 virus.
